Home » Stocks » VTGN

VistaGen Therapeutics, Inc. (VTGN)

Stock Price: $2.28 USD -0.06 (-2.56%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $2.30 +0.02 (0.88%) Jan 20, 7:57 PM
Market Cap 320.03M
Revenue (ttm) 334,000
Net Income (ttm) -16.98M
Shares Out 67.08M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $2.28
Previous Close $2.34
Change ($) -0.06
Change (%) -2.56%
Day's Open 2.34
Day's Range 2.17 - 2.36
Day's Volume 1,772,782
52-Week Range 0.32 - 2.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review...

GlobeNewsWire - 4 weeks ago

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of...

Benzinga - 4 weeks ago

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.

Other stocks mentioned: BCRX, TDOC
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines wit...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines wit...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and oth...

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

PRNewsWire - 5 months ago

SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 31, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, dep...

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and d...

Zacks Investment Research - 1 year ago

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

Zacks Investment Research - 1 year ago

VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.

Benzinga - 1 year ago

Vistagen Therapeutics Inc (NASDAQ: VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate.

About VTGN

VistaGen Therapeutics, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder w... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Shawn K. Singh
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
VTGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is 5.50, which is an increase of 141.23% from the latest price.

Price Target
$5.50
(141.23% upside)
Analyst Consensus: Strong Buy